Hey!I'm not under a gag order! I can yap as much as I ever did.
It's been busy for about 5 weeks now. Lot of stuff behind the scenes for a while, then the executive changes, then talking on the phone with shareholders 12 or 14 hours a day for 2 weeks, then off to Toronto for the second roadshow, got back to my desk on Thursday, which along with Friday, were two of the busiest days ever.
After the changes happened, there wasn't much I could say until I learned what the company's directions were going to be. I have had several conversations with Deborah Rathjen (DrDR) and I like very much what I've heard. But before posted here, I needed to hear what the public message was going to be and Toronto was the first opportunity for that.
Everybody knows there's a need for money and DrDR dealt with that head-on in Toronto. Management will continue to raise money as it's needed, from non-dilutive sources when possible, and by minimally dilutive means when absolutely needed. Could deals be in the mix? That's why we're in business. All of the Bioasis goals are related to the advancement of xB3, both through the advancement of internal development programs and the pursuit of business development deals to fund our objectives. I believe we have good people setting good goals for good reasons. That's usually a recipe for success.
I was pleased to hear DrDR indicate that consideration will be given to bringing a number of other pipeline candidates forward. These were not announcements as much as public speculations but it's clear that the pain treatment study undertaken by MedImmune is of great interest to her. Bioasis owns that drug so we have every right to bring it forward.
Taking some action on LSDs may also be considered. They have lingered in the background for a long time.
Gaucher Disease may be of particular interest.
A very interesting little scientific tidbit came up. As we know, xB3 attaches primarily to the LRP-1 receptor. This receptor can be found in numbers in various parts of the body which means that xB3 could be useful for the delivery of drugs to non-brain (peripheral) areas of the body. Caroline Clairmont mentioned this. She described cystic fibrosis as something that may be worth looking at. It may be possible to deliver drugs by injecting them instead of inhaling them, a method that ultimately causes damage to the air side of lung tissue.
With respect to Mark Day and Catherine London, there is nothing to be gained from wild-eyed speculations about them on this forum. They no longer work for the company. We have a new management intent on lowering management and administrative costs and putting more money into the science. I wish both Mark and Catherine well. But we have new management.
On with the job! Nothing stops. Full speed ahead chasing the dreams that we've always had, dreams that continue to be pursued, perhaps in a more focused, prudent and exciting way.
jdstox